James T Walkup1, Usha Sambamoorthi, Stephen Crystal. 1. Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, NJ 08901, USA. walkup@rci.rutgers.edu
Abstract
OBJECTIVES: The study compares rates of protease inhibitor (PI) use during the 3 years following the introduction of these newer treatments among human immunodeficiency virus (HIV)-infected individuals with and without serious mental illness and examines persistence of use of these therapies across these subgroups. METHOD: We used merged autoimmune deficiency syndrome (AIDS)/HIV surveillance and Medicaid claims data to examine use of PIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs) among New Jersey Medicaid beneficiaries with AIDS between 1996 and 1998. Based on the ICD-9-CM diagnoses assigned by a high-credibility source in 1 inpatient or 2 outpatient claims, we identified patients with schizophrenia (ICD-9-CM code 295) and those with severe affective disorder (combining patients with recurrent major depressive disorder [ICD-9-CM code 296.3] or bipolar disorder [296.4, 296.5, 296.6, 296.7, or 296.8]). These groups were compared with those patients with no serious mental illness. RESULTS: In this sample, patients with schizophrenia (68.3%) and those with severe affective disorder (75.6%) were more likely to have initiated new antiretroviral therapy than were those without serious mental illness (64.3%). Patients with severe affective disorder, but not those with schizophrenia, were significantly less persistent (p <.01) in their use of PI/NNRTI therapy than those without serious mental illness. CONCLUSIONS: No evidence was found that the presence of a serious mental illness discourages physicians from initiating new antiretroviral therapy, perhaps reflecting a comparatively high level of integration of these patients into the health care system. Patients with schizophrenia are as persistent in their use of PI/NNRTI therapy as those without a serious mental illness. Lower rates of medication compliance by those with severe affective disorder justify increased efforts to support optimal adherence.
OBJECTIVES: The study compares rates of protease inhibitor (PI) use during the 3 years following the introduction of these newer treatments among human immunodeficiency virus (HIV)-infected individuals with and without serious mental illness and examines persistence of use of these therapies across these subgroups. METHOD: We used merged autoimmune deficiency syndrome (AIDS)/HIV surveillance and Medicaid claims data to examine use of PIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs) among New Jersey Medicaid beneficiaries with AIDS between 1996 and 1998. Based on the ICD-9-CM diagnoses assigned by a high-credibility source in 1 inpatient or 2 outpatient claims, we identified patients with schizophrenia (ICD-9-CM code 295) and those with severe affective disorder (combining patients with recurrent major depressive disorder [ICD-9-CM code 296.3] or bipolar disorder [296.4, 296.5, 296.6, 296.7, or 296.8]). These groups were compared with those patients with no serious mental illness. RESULTS: In this sample, patients with schizophrenia (68.3%) and those with severe affective disorder (75.6%) were more likely to have initiated new antiretroviral therapy than were those without serious mental illness (64.3%). Patients with severe affective disorder, but not those with schizophrenia, were significantly less persistent (p <.01) in their use of PI/NNRTI therapy than those without serious mental illness. CONCLUSIONS: No evidence was found that the presence of a serious mental illness discourages physicians from initiating new antiretroviral therapy, perhaps reflecting a comparatively high level of integration of these patients into the health care system. Patients with schizophrenia are as persistent in their use of PI/NNRTI therapy as those without a serious mental illness. Lower rates of medication compliance by those with severe affective disorder justify increased efforts to support optimal adherence.
Authors: David J Moore; Carolina Posada; Mili Parikh; Miguel Arce; Florin Vaida; Patricia K Riggs; Ben Gouaux; Ronald J Ellis; Scott L Letendre; Igor Grant; J Hampton Atkinson Journal: AIDS Behav Date: 2012-11
Authors: Geetanjali Chander; YiYi Zhang; Susan dosReis; Donald M Steinwachs; Daniel E Ford; Eliseo Guallar; Gail Daumit Journal: J AIDS HIV Res Date: 2012-08
Authors: Maria Ferrara; Anya Umlauf; Chelsea Sanders; Jonathan M Meyer; John Allen McCutchan; Nichole Duarte; Joseph Hampton Atkinson; Igor Grant; Ronald J Ellis Journal: Psychiatry Res Date: 2014-04-18 Impact factor: 3.222
Authors: D M Coviello; R Lovato; K Apostol; M M Eisenberg; D S Metzger; R Szucs-Reed; N Kiryankova-Dalseth; D Kelly; A Jackson; M Plano; M B Blank Journal: Community Ment Health J Date: 2018-05-11
Authors: Seth Himelhoch; Clayton H Brown; James Walkup; Geetanjali Chander; P Todd Korthius; Joseph Afful; Kelly A Gebo Journal: AIDS Date: 2009-08-24 Impact factor: 4.177
Authors: W D King; P Minor; C Ramirez Kitchen; L E Oré; S Shoptaw; G D Victorianne; G Rust Journal: J Epidemiol Community Health Date: 2008-09 Impact factor: 3.710
Authors: Seth Himelhoch; Geetanjali Chander; John A Fleishman; James Hellinger; Paul Gaist; Kelly A Gebo Journal: Gen Hosp Psychiatry Date: 2007 Nov-Dec Impact factor: 3.238